Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
日本語
English
Русский
中文
Español
Português
Deutsch
한국어
Français
Italiano
Türkçe
HRMY
#1797
Harmony Biosciences Holdings, Inc. Common Stock
28.540
0
+0.25%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+0.25%
Changement Mensuel
-24.24%
Evolution sur 6 mois
-7.64%
Changement Annuel
-7.64%
Clôture Précédente
28.470
0
Open
28.540
0
Bid
Ask
Low
28.540
0
High
28.540
0
Volume
110
Marchés
Actions des Marchés US
Soins de Santé
HRMY
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
57.03 M
57.35 M
57.42 M
57.53 M
57.6 M
57.84 M
—
Valuation ratios
Enterprise value
1.89 B
1.52 B
1.42 B
1.27 B
940.36 M
1.41 B
5.04 B
Price to earnings ratio
18.87
13.71
12.67
10.19
8.67
13.81
45.34
Price to sales ratio
3.42
2.79
2.58
2.38
1.95
2.52
9.44
Price to cash flow ratio
10.63
9.06
8.64
7.09
5.41
6.29
27.43
Price to book ratio
1.1
3.02
0.77
0.67
0.54
2.52
4.49
Enterprise value to EBITDA ratio
8.78
7.12
6.02
4.85
3.53
6.1
20.5
Profitability ratios
Return on assets %
0.05
0.05
0.04
0.04
0.04
0.02
0.14
Return on equity %
0.08
0.08
0.06
0.05
0.06
0.03
0.2
Return on invested capital %
41.64
43.28
36.37
29.77
39.61
19.07
124.81
Gross margin %
77.01
72.97
82.68
80.97
75.09
71.88
310.62
Operating margin %
33.17
27.69
30.45
24.03
27.35
15.82
97.64
EBITDA margin %
36.18
39.38
33.52
26.86
29.77
25.55
115.7
Net margin %
24.78
24.58
24.66
19.84
21.24
9.22
74.97
Liquidity ratios
Quick ratio
3.2
3.27
3.63
3.8
3.72
3.58
14.74
Current ratio
3.24
3.31
3.67
3.84
3.75
3.6
14.86
Inventory turnover
6.81
7.71
4.71
6.11
9.19
11.2
31.21
Asset turnover
0.21
0.21
0.18
0.19
0.21
0.2
0.77
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.18
0.16
0.15
0.14
0.12
0.11
0.52
Long term debt to total equity ratio
0.28
0.25
0.22
0.2
0.18
0.17
0.76
Per share metrics
Operating cash flow per share
1.21
1.31
0.58
1.36
1.85
2.15
5.95
EBIT per share
1.06
0.96
0.96
0.82
1.12
0.66
3.56
EBITDA per share
1.16
1.37
1.06
0.92
1.21
1.06
4.26
Total debt per share
—
—
—
—
—
—
—
Cash per share
7.06
8.07
8.66
9.67
11.45
13.24
43.04
Net current asset value per share
8.99
10.01
10.98
11.83
14.29
15.49
52.59
Tangible book value per share
8.22
9.43
10.48
11.5
12.6
13.34
47.91
Working capital per share
6.22
6.98
7.99
8.75
10.48
11.19
38.41
Book value per share
10.27
11.39
12.31
13.23
14.22
14.86
54.63
Nouvelles
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
Corcept's Q4 Earnings and Revenues Fall Short of Estimates
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
UBS、Wakixジェネリック早期参入でHarmony Biosciences目標株価引き下げ
UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry
Truist、Harmony Biosciences株にHold評価を継続、目標株価25ドルを設定
Truist reiterates Hold on Harmony Biosciences stock, sets $25 target
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market